ไอซ์แลนด์ -
ไอซ์แลนด์ -
LYFJASTOFNUN (Icelandic Medicines Agency)
synthadon vet. stungulyf, lausn 10 mg/ml
le vet beheer b.v. - methadonum hýdróklóríð - stungulyf, lausn - 10 mg/ml
ไอซ์แลนด์ -
ไอซ์แลนด์ -
LYFJASTOFNUN (Icelandic Medicines Agency)
metadon abcur (metadon novum abcur) tafla 40 mg
abcur ab* - methadonum hýdróklóríð - tafla - 40 mg
ไอซ์แลนด์ -
ไอซ์แลนด์ -
LYFJASTOFNUN (Icelandic Medicines Agency)
metadon abcur (metadon novum abcur) tafla 10 mg
abcur ab* - methadonum hýdróklóríð - tafla - 10 mg
ไอซ์แลนด์ -
ไอซ์แลนด์ -
LYFJASTOFNUN (Icelandic Medicines Agency)
metadon abcur (metadon novum abcur) tafla 20 mg
abcur ab* - methadonum hýdróklóríð - tafla - 20 mg
ไอซ์แลนด์ -
ไอซ์แลนด์ -
LYFJASTOFNUN (Icelandic Medicines Agency)
metadon abcur (metadon novum abcur) tafla 5 mg
abcur ab* - methadonum hýdróklóríð - tafla - 5 mg
ไอซ์แลนด์ -
ไอซ์แลนด์ -
LYFJASTOFNUN (Icelandic Medicines Agency)
metadon 2care4 tafla 10 mg
2care4 generics aps - methadonum hýdróklóríð - tafla - 10 mg
ไอซ์แลนด์ -
ไอซ์แลนด์ -
LYFJASTOFNUN (Icelandic Medicines Agency)
metadon 2care4 tafla 20 mg
2care4 generics aps - methadonum hýdróklóríð - tafla - 20 mg
ไอซ์แลนด์ -
ไอซ์แลนด์ -
LYFJASTOFNUN (Icelandic Medicines Agency)
metadon 2care4 tafla 5 mg
2care4 generics aps - methadonum hýdróklóríð - tafla - 5 mg
สหภาพยุโรป -
ไอซ์แลนด์ -
EMA (European Medicines Agency)
zubsolv
accord healthcare s.l.u. - buprenorphine hydrochloride, naloxone hydrochloride dihydrate - Ópíóíð-tengdir sjúkdómar - Önnur lyf í taugakerfinu - skiptingarmeðferð við ópíóíðlyfjafíkn, innan ramma læknisfræðilegrar, félagslegrar og sálfræðilegrar meðferðar. tilgangur naloxónefnisins er að hindra misnotkun í bláæð. meðferð er ætluð til notkunar hjá fullorðnum og unglingum eldri en 15 ára sem hafa samþykkt að fá meðferð vegna fíkn.
สหภาพยุโรป -
ไอซ์แลนด์ -
EMA (European Medicines Agency)
scemblix
novartis europharm limited - asciminib hydrochloride - kyrningahvítblæði, mergbreytilegt, langvinnt, bcr-abl jákvætt - Æxlishemjandi lyf - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.